Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.41 |
| ▸ | GSK3B | P49841 | 8/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ICOSLG | O75144 | 1/20 | 0.35 |
| ▸ | ICOS | Q9Y6W8 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760435 | 0.91 | DYRK1A (0.45) | DYRK1AGSK3BGRM5CLK2CLK3 | |
| SCHEMBL6804372 | 0.90 | DYRK1A (0.45) | DYRK1AGSK3BCLK2CLK3IDO1 | |
| SCHEMBL6755618 | 0.89 | DYRK1A (0.40) | DYRK1AGSK3BGRM5 | |
| SCHEMBL6756890 | 0.85 | DYRK1A (0.44) | DYRK1AGSK3BGRM5MAPK1CLK2 | |
| SCHEMBL6755637 | 0.81 | MAPT (0.45) | DYRK1AGSK3B | |
| SCHEMBL6803727 | 0.80 | DYRK1A (0.46) | DYRK1AGSK3BGRM5CLK2CLK3 | |
| SCHEMBL6833169 | 0.73 | DYRK1A (0.44) | DYRK1AGSK3BGRM5CLK2CLK3 | |
| SCHEMBL6805348 | 0.72 | DYRK1A (0.43) | DYRK1AGSK3BGRM5CLK2CLK3 | |
| SCHEMBL6754360 | 0.72 | DYRK1A (0.45) | DYRK1AGSK3BGRM5MAPK1KAT5 | |
| SCHEMBL6832909 | 0.72 | RAB9A (0.42) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | DYRK1A 3409/4885GSK3B 4671/4885GRM5 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.